Catalyst calendar
Data as of 2026-08-19 16:00 UTC · tracked universe polled every 15 minutes
Three kinds of date: a PDUFA date (the deadline the FDA sets itself to decide on a drug application), an AdCom (an FDA advisory-committee meeting that reviews it in public), and a readout window (when a trial's results are expected). Dates marked confirmed by the company come from an 8-K or press-release quote; our estimate is a rule-derived window off the trial's registered primary-completion date (see methodology) — never shown the same way. Today: 200 estimated readout windows and 0 disclosed PDUFA/AdCom dates.
Next 7 days
| Date | Ticker | Phase | Event |
|---|---|---|---|
| 2026-10-30 in 10w | $MRTX | Phase 2 | Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation… NCT05853575 |
| 2026-10-30 in 10w | $VRTX | Phase 3 | A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination… NCT05444257 |
| 2026-10-31 in 10w | $SRPT | Phase 3 | A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in… NCT03992430 |
| 2026-10-31 in 10w | $AMGN | Phase 2 | A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced… NCT06593522 |
| 2026-11-01 in 11w | $BMY | Phase 3 | A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic… NCT06951698 |
| 2026-11-02 in 11w | $REGN | Phase 2 | A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than… NCT06190951 |
| 2026-11-02 in 11w | $BMY | Phase 3 | A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic… NCT06951711 |
| 2026-11-05 in 11w | $INCY | Phase 2 | Rollover Study to Provide Continued Treatment for Participants With B-Cell… NCT04509700 |
| 2026-11-13 in 12w | $REGN | Phase 2 | Study of Olatorepatide in Adult Participants Living With Overweight or Obesity… NCT07431086 |
| 2026-11-18 in 13w | $BMY | Phase 3 | A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With… NCT05946941 |
| 2026-11-20 in 13w | $INCY | Phase 2 | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in… NCT05851443 |
| 2026-11-29 in 15w | $PFE | Phase 3 | A Study to Learn About the Study Medicine Called Rimegepant in Women When Used… NCT06641466 |
| 2026-12-01 in 15w | $BIIB | Phase 3 | A Study to Learn More About the Effects and Safety of Felzartamab Infusions in… NCT06685757 |
| 2026-12-02 in 15w | $PFE | Phase 3 | A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6… NCT07029711 |
| 2026-12-02 in 15w | $PFE | Phase 3 | A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic… NCT06629779 |
| 2026-12-03 in 15w | $REGN | Phase 2 | A Study to Test the Safety, Tolerability, and Efficacy of an Antibody,… NCT06421636 |
| 2026-12-14 in 17w | $AMGN | Phase 3 | Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab) NCT06430866 |
| 2026-12-26 in 18w | $INCY | Phase 3 | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in… NCT06212999 |
| 2026-12-29 in 19w | $REGN | Phase 2 | A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult… NCT07477704 |
| 2026-12-30 in 19w | $VRTX | Phase 2 | Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With… NCT06794996 |
| 2026-12-31 in 19w | $VIR | Phase 3 | A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection NCT06903338 |
| 2026-12-31 in 19w | $BPMC | Phase 2 | Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous… NCT06931405 |
| 2027-01-21 in 22w | $AMGN | Phase 3 | Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2… NCT06858839 |
| 2027-01-21 in 22w | $AMGN | Phase 3 | Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type… NCT06858878 |
| 2027-01-25 in 23w | $VRTX | Phase 3 | Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in… NCT06696443 |